Vaginal DHEA to treat menopause related atrophy: A review of the evidence

Maturitas

Volumn 70, Issue 1, 2011, Pages 22-25

  Panjari, Mary ^a   Davis, Susan R ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

DHEA DHEAS; Intravaginal; Menopause; Vaginal atrophy

Indexed keywords

AROMATASE INHIBITOR; CONJUGATED ESTROGEN; ESTRADIOL; ESTRIOL; ESTROGEN; FOLLITROPIN; LUTEINIZING HORMONE; PRASTERONE; TESTOSTERONE;

ARTICLE; BREAST CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM; ESTRADIOL BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; PATIENT COMPLIANCE; POSTMENOPAUSE; SEXUAL FUNCTION; UNSPECIFIED SIDE EFFECT; VAGINA ATROPHY; VAGINAL DRYNESS;

EID: 80051783908     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2011.06.005     Document Type: Review

References (46)

1. G.A. Bachmann, and N.S. Nevadunsky Diagnosis and treatment of atrophic vaginitis American Family Physician 61 May (10) 2000 3090 3096 (Pubitemid 30347020)
2. R. Raz, and W.E. Stamm A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections New England Journal of Medicine 329 September (11) 1993 753 756 (Pubitemid 23262529)
3. N.E. Avis, S. Brockwell, and J.F. Randolph Jr. Longitudinal changes in sexual functioning as women transition through menopause: results from the study of women's health across the nation Menopause 16 May-June (3) 2009 442 452
4. N. Wines, and E. Willsteed Menopause and the skin Australasian Journal of Dermatology 42 August (3) 2001 149 158 quiz 59
5. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of the North American Menopause Society. Menopause 2007;14(May-June (3) Pt 1):355-69; quiz 70-1.
6. J.-P. Bergerat Aromatase inhibitors in the adjuvant treatment of early breast cancer. Is there still a place for tamoxifen? Presse Medicale 36 February (2 Pt 2) 2007 333 340 (Pubitemid 46528883)
7. T. Symington, W.P. Duguid, and J.N. Davidson Effect of exogenous corticotropin on the histochemical pattern of the human adrenal cortex and a comparison with the changes during stress Journal of Clinical Endocrinology and Metabolism 16 May (5) 1956 580 598
8. P.F. Hall, C.C. Sozer, and K.B. Eik-Nes Formation of dehydroepiandrosterone during in vivo and in vitro biosynthesis of testosterone by testicular tissue Endocrinology 74 January 1964 35 43
9. A. Aakvaag, A.A. Hagen, and K.B. Eik-Nes Biosynthesis in vivo of testosterone and delta-4-androstenedione from dehydroepiandrosterone-sodium sulfate by the canine testis and ovary Biochimica et Biophysica Acta 86 June 1964 622 627
10. E.E. Baulieu Neurosteroids: a novel function of the brain Psychoneuroendocrinology 23 November (8) 1998 963 987 (Pubitemid 29049302)
11. F. Labrie, V. Luu-The, and C. Labrie Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone Endocrine Reviews 24 2003 152
12. D. Liu, and J.S. Dillon Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2 3) Journal of Biological Chemistry 277 June (24) 2002 21379 21388 (Pubitemid 34952278)
13. D. Liu, and J.S. Dillon Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor Steroids 69 April (4) 2004 279 289 (Pubitemid 38748724)
14. E.R. Simpson, and S.R. Davis Minireview: aromatase and the regulation of estrogen biosynthesis - some new perspectives Endocrinology 142 November (11) 2001 4589 4594 (Pubitemid 33022332)
15. J. Suckling, A. Lethaby, and R. Kennedy Local oestrogen for vaginal atrophy in postmenopausal women Cochrane Database of Systematic Reviews 4 2006 CD001500
16. C. Lynch Vaginal estrogen therapy for the treatment of atrophic vaginitis Journal of Womens Health (Larchmt) 18 October (10) 2009 1595 1606
17. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of the North American menopause society. Menopause 2007;14(March-April (2)):168-82.
18. E. Weisberg, R. Ayton, and G. Darling Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet Climacteric 8 March (1) 2005 83 92 (Pubitemid 40675125)
19. J.E. Rioux, C. Devlin, M.M. Gelfand, W.M. Steinberg, and D.S. Hepburn 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis Menopause 7 May-June (3) 2000 156 161 (Pubitemid 30249896)
20. J. Simon, L. Nachtigall, R. Gut, E. Lang, D.F. Archer, and W. Utian Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet Obstetrics and Gynecology 112 November (5) 2008 1053 1060
21. G. Bachmann, R.A. Lobo, R. Gut, L. Nachtigall, and M. Notelovitz Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial Obstetrics and Gynecology 111 January (1) 2008 67 76
22. G.L. Anderson, R.T. Chlebowski, and J.E. Rossouw Prior hormone therapy and breast cancer risk in the women's health initiative randomized trial of estrogen plus progestin Maturitas 55 September (2) 2006 103 115 (Pubitemid 44307491)
23. G.L. Anderson, M. Limacher, and A.R. Assaf Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial Journal of the American Medical Association 291 April (14) 2004 1701 1712 (Pubitemid 38489892)
24. R.T. Chlebowski, L.H. Kuller, and R.L. Prentice Breast cancer after use of estrogen plus progestin in postmenopausal women New England Journal of Medicine 360 February (6) 2009 573 587
25. J.E. Rossouw, G.L. Anderson, and R.L. Prentice Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial Journal of the American Medical Association 288 July (3) 2002 321 333 (Pubitemid 34761611)
26. R.J. Santen, D.C. Allred, and S.P. Ardoin Postmenopausal hormone therapy: an endocrine society scientific statement Journal of Clinical Endocrinology and Metabolism 95 July (7 Suppl. 1) 2010 s1 s66
27. V. Beral, G. Reeves, D. Bull, and J. Green Breast cancer risk in relation to the interval between menopause and starting hormone therapy Journal of the National Cancer Institute 103 February (4) 2011 296 305
28. F. Labrie, L. Cusan, and J.L. Gomez Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women Menopause 16 January-February (1) 2009 30 36
29. A. Kendall, M. Dowsett, E. Folkerd, I. Smith, and Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors Annals of Oncology 17 April (4) 2006 584 587
30. G. Pfeiler, C. Glatz, and R. Konigsberg Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients Climacteric 14 June (3) 2011 339 344
31. S. Witherby, J. Johnson, and L. Demers Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study Oncologist 16 4 2011 424 431
32. C. Raghunandan, S. Agrawal, P. Dubey, M. Choudhury, and A. Jain A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women Journal of Sexual Medicine 7 March (3) 2010 1284 1290
33. S.R. Davis, M. Panjari, and F.Z. Stanczyk DHEA replacement for postmenopausal women Journal of Clinical Endocrinology and Metabolism March 2011
34. M. Panjari, and S.R. Davis DHEA for postmenopausal women: a review of the evidence Maturitas 66 June (2) 2010 172 179
35. L. Berger, M. El-Alfy, and F. Labrie Effects of intravaginal dehydroepiandrosterone on vaginal histomorphology, sex steroid receptor expression and cell proliferation in the rat Journal of Steroid Biochemistry and Molecular Biology 109 1-2 2008 67 80
36. F. Labrie, P. Diamond, L. Cusan, J.-L. Gomez, A. Belanger, and B. Candas Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina and endometrium in postmenopausal women Journal of Clinical Endocrinology and Metabolism 82 10 1997 3498 3505 (Pubitemid 27419111)
37. E. Suh-Burgmann, J. Sivret, L.R. Duska, M. Del Carmen, and M.V. Seiden Long-term administration of intravaginal dehydroepiandrosterone on regression of low-grade cervical dysplasia - a pilot study Gynecologic and Obstetric Investigation 55 1 2003 25 31 (Pubitemid 36302386)
38. P.R. Casson, A.B. Straughn, E.S. Umstot, G.E. Abraham, S.A. Carson, and J.E. Buster Delivery of dehydroepiandrosterone to premenopausal women: effects of micronization and nonoral administration American Journal of Obstetrics and Gynecology 174 2 1996 649 653 (Pubitemid 26070159)
39. F. Labrie, L. Cusan, and J.L. Gomez Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women Journal of Steroid Biochemistry and Molecular Biology 111 3-5 2008 178 194
40. F. Labrie, D. Archer, and C. Bouchard Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration Menopause 16 September-October (5) 2009 897 906
41. F. Labrie, D. Archer, and C. Bouchard Intravaginal dehydroepiandrosterone (Prasterone), a physiological and a highly efficient treatment of vaginal atrophy Menopause May 2009
42. F. Labrie, D. Archer, and C. Bouchard Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women Menopause May 2009
43. F. Labrie, D. Archer, and C. Bouchard High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy Gynecological Endocrinology 26 7 2010 524 532
44. F. Labrie, D.F. Archer, and C. Bouchard Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia Climacteric 14 April (2) 2011 282 288
45. M. Panjari, R.J. Bell, F. Jane, J. Adams, C. Morrow, and S.R. Davis The safety of 52 weeks of oral DHEA therapy for postmenopausal women Maturitas 63 July (3) 2009 240 245
46. P.M. Baxendale, M.J. Reed, and V.H. James Inability of human endometrium or myometrium to aromatize androstenedione Journal of Steroid Biochemistry 14 March (3) 1981 305 306 (Pubitemid 11159291)